Hospira Inc Issues A Voluntary Nationwide Recall For Buprenorphine Hydrochloride Injection CarpujectTM Units and Labetalol Hydrochloride Injection, USP CarpujectTM Units Due to the Potential for Incomplete Crimp Seals fda.gov - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fda.gov Daily Mail and Mail on Sunday newspapers.
FOR IMMEDIATE RELEASE - May 21, 2024 - NEW YORK, NY., Hospira, Inc., a Pfizer company , is voluntarily recalling the lots listed in the table below of Buprenorphine Hydrochloride Injection CarpujectTM.
MarketsandResearch.biz recently introduced a new title on
Global Buprenorphine Hydrochloride Injection Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026 from its database. The report provides a study with an in-depth overview, describing the product/industry scope and elaborates market outlook and status (2021-2026). The report is curated after in-depth research and analysis by experts. The report provides comprehensive valuable insights on the global Buprenorphine Hydrochloride Injection market development activities demonstrated by industry players, growth opportunities, and market sizing with analysis by key segments, leading and emerging players, and geographies.
The report contains a methodical explanation of current market trends to assist the users to entail an in-depth market analysis. The study helps in identifying and tracking emerging players in the global Buprenorphine Hydrochloride Injection market and their portfolios, to enhance decision-